Glycovax Pharma
Shaping Drug Development with Medical Glycobiology

Glycans, the sugar chains linked to proteins and lipids, are crucial in regulating biological processes. While scientific research focuses primarily on proteins and genomics, progress in the field of glycobiology has been relatively slower and the biological roles of glycans largely underestimated.

Recognizing this opportunity, Glycovax Pharma has seized the opportunity by developing novel therapeutic approaches that harness glycan’s potential. The company focuses on advancing innovative solutions for treatment of cancer and tackling infectious diseases, such as bacterial and viral diseases, by using glycans as vaccine targets.

The term Glycovax stems from the words ‘glycan’ and ‘vaccine.’ The company’s research and development (R&D) efforts center on exploiting glycans, specifically oligosaccharides that modify proteins, as potential vaccine targets. The firm addresses indications in oncology and infectious diseases, particularly those caused by viral pathogens. These types of vaccines possess a significant edge due to their versatility in targeting specific glycan antigens shared among diverse cancers and viruses, making it a valuable option for treating multiple diseases.

“Our differentiating factor lies in our scientific approach that focuses on targeting glycans, setting us apart from other companies that are primarily focused on protein-based treatments,” says Dr. Serge Moffett, scientific director at Glycovax Pharma.

And to overcome the challenges of early-stage companies developing a product in-house from bench research to clinical, Glycovax integrates expertise in all aspects of scientific research with regulatory in-house clinical expertise and leadership in business as its strategy to operate a bioscience company successfully.

While acknowledging the inherent limitations and risky approach of the glycan strategy, Glycovax firmly believes in its potential to overcome challenges faced by other approaches, such as the novel mRNA vaccine strategy. Subsequently, the firm’s primary objective is to advance its product portfolio through phase 2 clinical trials, ultimately securing licensing agreements with prominent industry players in the vaccine field.

Founded by a team of glycochemists specializing in the chemical synthesis of aberrant glycan structures that are exclusive to cancer cells and viruses, Glycovax addresses the challenge of isolating and purifying these structures from biological sources.

Glycovax distinguishes itself from other personalized medicine companies by targeting the glycan portion of proteins instead of concentrating only on the unique amino acid portion of specific proteins. The business model involves consolidating the necessary in-house expertise from R&D to clinical stages, expediting the development process by being proactive in the early stages. Glycovax further solves the issues early-stage drug developers face by managing all stages of drug development in-house through integrated operations while minimizing the use of CRO.

Glycovax engages itself in the development of a commercial arm, focusing on the production of a crucial glycoconjugate vaccine component for its proprietary vaccines. Simultaneously, the company extends the offering to other vaccine developers from the same domain. This strategic approach serves multiple purposes, including generating financial resources to support ongoing R&D endeavours and fostering potential partnerships within the industry.

Apart from its unique scientific approach in R&D, Glycovax has established a comprehensive company structure that integrates expertise across the multiple facets of drug development. Its inherent advantage is rooted in its status as a fully integrated company equipped with the necessary resources for comprehensive drug development in the field of glycoscience. It allows organizations to co-develop, where it can advance projects initiated by others who may lack expertise in more advanced stages, particularly in regulatory affairs and clinical development.

Driven by a compelling mission to establish glycoscience as a catalyst for future therapeutic advancements, Glycovax draws inspiration from the transformative impact of mRNA vaccines in combating diseases like COVID-19 and addressing various infectious diseases and cancers. By harnessing the power of glycoscience, the company hopes to pave the way for significant breakthroughs in the field of therapeutics.